+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Critical Limb Ischemia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019-2027

  • ID: 4851500
  • Report
  • May 2019
  • Region: Global
  • 166 pages
  • Transparency Market Research
1 of 2

Global Critical Limb Ischemia Treatment Market: Overview 

This report analyzes the current and future scenario of the global critical limb ischemia treatment market. Increase in patient population with critical limb ischemia, growth of the pharmaceutical industry, improvement in health care infrastructure, and increase in the number of clinical trials are projected to be the major drivers of the global market during the forecast period. 

The global critical limb ischemia treatment market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, and region. A detailed qualitative analysis of drivers and restraints of the market, and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the global critical limb ischemia treatment market. 

Global Critical Limb Ischemia Treatment Market: Key Segments

Based on treatment, the global critical limb ischemia treatment market has been segmented into devices and medications. The segments have been analyzed based on available devices and drug products used in the treatment of critical limb ischemia, cost-effectiveness, and preference for industries. The market size and forecast for each of these segments have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year. 

Global Critical Limb Ischemia Treatment Market: Regional Outlook

In terms of region, the global critical limb ischemia treatment market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2018 as the base year. The research study also covers the competitive scenario in these regions. 

Companies Mentioned in Report

The report also profiles major players in the global critical limb ischemia treatment market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players profiled in the market report include Medtronic plc, Boston Scientific Corporation, Cesca Therapeutics, Inc., Abbott Laboratories, Pluristem Therapeutics, Inc., Rexgenero Ltd., LimFlow SA, Micro Medical Solutions, and Cardiovascular Systems, Inc. 

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights

2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary

4. Market Overview
4.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers and Restraints Snapshot Analysis
4.2.2. Drivers
4.2.3. Restraints
4.2.4. Opportunity
4.3. Global Critical Limb Ischemia Treatment Market Revenue Projection (US$ Mn), 2017-2027
4.4. Global Critical Limb Ischemia Treatment Market Outlook

5. Market Outlook
5.1. Pipeline Analysis
5.2. Key Industry Events
5.3. Regulatory Scenario for Device
5.4. Prevalence of Critical Limb Ischemia Globally/Region
5.5. Major Research Institutes Involved
5.6. Technological Advancement

6. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment
6.1. Key Findings
6.2. Introduction
6.3. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
6.4. Global Critical Limb Ischemia Treatment Market Forecast, by Treatment
6.4.1. Devices
6.4.1.1. Embolic Protection Devices
6.4.1.2. Peripheral Dilatation Systems
6.4.1.2.1. Balloon Dilators
6.4.1.2.2. Vascular stents
6.4.2. Medications
6.4.2.1. Antiplatelet Drugs
6.4.2.2. Antihypertensive Agents
6.4.2.3. Lipid-lowering Agents
6.4.2.4. Antithrombotic Agents
6.4.2.5. Others
6.5. Global Critical Limb Ischemia Treatment Market Analysis, by Treatment

7. Global Critical Limb Ischemia Treatment Market Analysis, by Region
7.1. Global Critical Limb Ischemia Treatment Market Scenario, by Country
7.2. Global Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Region
7.3. Global Critical Limb Ischemia Treatment Market Forecast, by Region
7.3.1. North America
7.3.2. Europe
7.3.3. Asia Pacific
7.3.4. Latin America
7.3.5. Middle East & Africa

8. North America Critical Limb Ischemia Treatment Market Analysis
8.1. Key Findings
8.2. North America Critical Limb Ischemia Treatment Market Overview
8.3. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country
8.4. North America Critical Limb Ischemia Treatment Market Forecast, by Country
8.4.1. U.S.
8.4.2. Canada
8.5. North America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
8.6. North America Critical Limb Ischemia Treatment Market Forecast, by Treatment
8.6.1. Devices
8.6.1.1. Embolic Protection Devices
8.6.1.2. Peripheral Dilatation Systems
8.6.1.2.1. Balloon Dilators
8.6.1.2.2. Vascular stents
8.6.2. Medications
8.6.2.1. Antiplatelet Drugs
8.6.2.2. Antihypertensive Agents
8.6.2.3. Lipid-lowering Agents
8.6.2.4. Antithrombotic Agents
8.6.2.5. Others

9. Europe Critical Limb Ischemia Treatment Market Analysis
9.1. Key Findings
9.2. Europe Critical Limb Ischemia Treatment Market Overview
9.3. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
9.4. Europe Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
9.4.1. Germany
9.4.2. France
9.4.3. U.K.
9.4.4. Italy
9.4.5. Spain
9.4.6. Rest of Europe
9.5. Europe Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
9.6. Europe Critical Limb Ischemia Treatment Market Forecast, by Treatment
9.6.1. Devices
9.6.1.1. Embolic Protection Devices
9.6.1.2. Peripheral Dilatation Systems
9.6.1.2.1. Balloon Dilators
9.6.1.2.2. Vascular stents
9.6.2. Medications
9.6.2.1. Antiplatelet Drugs
9.6.2.2. Antihypertensive Agents
9.6.2.3. Lipid-lowering Agents
9.6.2.4. Antithrombotic Agents
9.6.2.5. Others

10. Asia Pacific Critical Limb Ischemia Treatment Market Analysis
10.1. Key Findings
10.2. Asia Pacific Critical Limb Ischemia Treatment Market Overview
10.3. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.4. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia & New Zealand
10.4.5. Rest of Asia Pacific
10.5. Asia Pacific Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
10.6. Asia Pacific Critical Limb Ischemia Treatment Market Forecast, by Treatment
10.6.1. Devices
10.6.1.1. Embolic Protection Devices
10.6.1.2. Peripheral Dilatation Systems
10.6.1.2.1. Balloon Dilators
10.6.1.2.2. Vascular stents
10.6.2. Medications
10.6.2.1. Antiplatelet Drugs
10.6.2.2. Antihypertensive Agents
10.6.2.3. Lipid-lowering Agents
10.6.2.4. Antithrombotic Agents
10.6.2.5. Others

11. Latin America Critical Limb Ischemia Treatment Market Analysis
11.1. Key Findings
11.2. Latin America Critical Limb Ischemia Treatment Market Overview
11.3. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.4. Latin America Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Rest of Latin America
11.5. Latin America Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
11.6. Latin America Critical Limb Ischemia Treatment Market Forecast, by Treatment
11.6.1. Devices
11.6.1.1. Embolic Protection Devices
11.6.1.2. Peripheral Dilatation Systems
11.6.1.2.1. Balloon Dilators
11.6.1.2.2. Vascular stents
11.6.2. Medications
11.6.2.1. Antiplatelet Drugs
11.6.2.2. Antihypertensive Agents
11.6.2.3. Lipid-lowering Agents
11.6.2.4. Antithrombotic Agents
11.6.2.5. Others

12. Middle East & Africa Critical Limb Ischemia Treatment Market Analysis
12.1. Key Findings
12.2. Middle East & Africa Critical Limb Ischemia Treatment Market Overview
12.3. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.4. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Country/Sub-region
12.4.1. GCC Countries
12.4.2. South Africa
12.4.3. Rest of Middle East & Africa
12.5. Middle East & Africa Critical Limb Ischemia Treatment Market Value Share and Attractiveness Analysis, by Treatment
12.6. Middle East & Africa Critical Limb Ischemia Treatment Market Forecast, by Treatment
12.6.1. Devices
12.6.1.1. Embolic Protection Devices
12.6.1.2. Peripheral Dilatation Systems
12.6.1.2.1. Balloon Dilators
12.6.1.2.2. Vascular stents
12.6.2. Medications
12.6.2.1. Antiplatelet Drugs
12.6.2.2. Antihypertensive Agents
12.6.2.3. Lipid-lowering Agents
12.6.2.4. Antithrombotic Agents
12.6.2.5. Others

13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profile
13.2.1. Medtronic plc
13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.1.2. Financial Overview
13.2.1.3. Product Portfolio
13.2.1.4. SWOT Analysis
13.2.1.5. Strategic Overview
13.2.2. Boston Scientific Corporation
13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.2.2. Financial Overview
13.2.2.3. Product Portfolio
13.2.2.4. SWOT Analysis
13.2.2.5. Strategic Overview
13.2.3. Cesca Therapeutics, Inc.
13.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.3.2. Financial Overview
13.2.3.3. Product Portfolio
13.2.3.4. SWOT Analysis
13.2.3.5. Strategic Overview
13.2.4. Abbott Laboratories
13.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.4.2. Financial Overview
13.2.4.3. Product Portfolio
13.2.4.4. SWOT Analysis
13.2.4.5. Strategic Overview
13.2.5. Pluristem Therapeutics, Inc.
13.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.5.2. Financial Overview
13.2.5.3. Product Portfolio
13.2.5.4. SWOT Analysis
13.2.5.5. Strategic Overview
13.2.6. Rexgenero Ltd.
13.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.6.2. Financial Overview
13.2.6.3. Product Portfolio
13.2.6.4. SWOT Analysis
13.2.6.5. Strategic Overview
13.2.7. LimFlow SA
13.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.7.2. Financial Overview
13.2.7.3. Product Portfolio
13.2.7.4. SWOT Analysis
13.2.7.5. Strategic Overview
13.2.8. Micro Medical Solutions
13.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.8.2. Financial Overview
13.2.8.3. Product Portfolio
13.2.8.4. SWOT Analysis
13.2.8.5. Strategic Overview
13.2.9. Cardiovascular System, Inc.
13.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
13.2.9.2. Financial Overview
13.2.9.3. Product Portfolio
13.2.9.4. SWOT Analysis
13.2.9.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll